Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation

Investigative Radiology

Volumn 49, Issue 10, 2014, Pages 685-690

  Errante, Yuri ^a   Cirimele, Vincenzo ^a   Mallio, Carlo Augusto ^a   Di Lazzaro, Vincenzo ^a   Zobel, Bruno Beomonte ^a   Quattrocchi, Carlo Cosimo ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Contrast agent; Cumulative doses; Dentate nucleus; Gadolinium; Magnetic resonance; Signal intensity

Indexed keywords

GADODIAMIDE; CHELATING AGENT; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADULT; ARTICLE; BRAIN METASTASIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DENTATE NUCLEUS; FEMALE; HUMAN; IMAGE ANALYSIS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PONS; PRIORITY JOURNAL; BRAIN TUMOR; CEREBELLUM NUCLEUS; CHEMISTRY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SECONDARY;

BRAIN NEOPLASMS; CEREBELLAR NUCLEI; CHELATING AGENTS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES;

EID: 84925745727     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000072     Document Type: Article

References (25)

1. Uusisaari M, De Schutter E. The mysterious microcircuitry of the cerebellar nuclei. J Physiol. 2011;589:3441-3457.
2. Heck DH, De Zeeuw CI, Jaeger D, et al. The neuronal code (s) of the cerebellum. J Neurosci. 2013;33:17603-17609.
3. Sultan F, Hamodeh S, and Baizer JS. The human dentate nucleus. A complex shape untangled. Neuroscience. 2010;167:965-968.
4. Roccatagliata L, Vuolo L, Bonzano L, et al. Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology. 2009;251:503-510.
5. Kasahara S, Miki Y, Kanagaki M, et al. Hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with a history of brain irradiation. Radiology. 2011;258:222-228.
6. Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced t1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2013;270:834-841.
7. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
8. Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006;27:455-461.
9. Gagnon AL, Desai T. Dermatological diseases in patients with chronic kidney disease. J Nephropathol. 2013;2:104-109.
10. Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep. 2008;10:195-204.
11. Amet S, Launay-Vacher V, Clement O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the prospective fibrose nephrogenique systemique study. Invest Radiol. 2014;49:109-115.
12. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, et al. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol. 2011;46:48-56.
13. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984;16:167-172.
14. Van Wagoner M, O'Toole M, Worah D, et al. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol. 1991;26:980-986.
15. McLachlan SJ, Eaton S, De Simone DN. Pharmacokinetic behavior of gadoteridol injection. Invest Radiol. 1992;27:S12-S15.
16. Van Wagoner M, Worah D. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent. Invest Radiol. 1993;28:S44-S48.
17. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009;30:1259-1267.
18. Greenberg SA. Zinc transmetallation and gadolinium retention after MR imaging: case report. Radiology. 2010;257:670-673.
19. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol. 1996;31:739-742.
20. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
21. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol. 2004;39:138-142.
22. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol. 2006;41:272-278.
23. Fretellier N, Idee JM, Guerret S, et al. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol. 2011;46:85-93.
24. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372-380.
25. Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol. 2010;45:507-112.